New trends in patient management: risk-based therapy for febrile patients with neutropeniaFever and neutropenia –how to use a new treatment strategyA double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile

Kenneth VI Rolston; Robert W Finberg; James A Talcott; Alison Freifeld; Donna Marchigiani; Thomas Walsh; Winfried V Kern; Alain Cometta; Robrecht de Bock; Ronald Feld

2000, Number 2

<< Back Next >>

Enf Infec Microbiol 2000; 20 (2)

New trends in patient management: risk-based therapy for febrile patients with neutropenia
Fever and neutropenia –how to use a new treatment strategy
A double blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile

Rolston KVI, Finberg RW, Talcott JA, Freifeld A, Marchigiani D, Wals T, Kern WV, Cometta A, de Bock R, Feld R

Full text

How to cite this article

Language: Spanish
References: 22
Page: 61-80
PDF size: 98.79 Kb.

Text Extraction

No abstract

REFERENCES

Wade JC, Schimpff SC, Newman KA, Wiernik PH. Staphylococcus epidermidis: An increased cause of infection in patientswith granulocytopenia. Ann Intern Med 1982;96:503-8.
EORTC International Antimicrobial Therapy Cooperative Group. Gram-positive bacteremia in granulocytopenic cancer patients. Eur J Cancer 1990;26:569-74.
Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: A case-control study of predisposing factors. Clin Infect Dis 1992;14:1201-7.
Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997;25:247-59.
Press OW, Ramsey PG, Larson EB, Fefer A, Hickman RO. Hickman catheter infections in patients with malignancies. Medicine 1984;63:189-200.
Dompeling EC, Donnelly JP, Deresinski SC, Feld R, Lane-Allman EF, De Pauw BE. Early identification of neutropenic patients at risk of gram-positive bacteremia and the impact of empirical administration of vancomycin. Eur J Cancer 1996;32A:1332-9.
Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997;25:551-73.
International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Reduction of fever and Streptococcus bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin vs a placebo combined with pefloxacin. JAMA 1994;272: 1183-9.
Bow EJ, Mandel LA, Louie TJ, et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: Effect of augmented gram-positive activity on infectious morbidity. Ann Intern Med 1996;125:183-90.
Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA. Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 1988;108:30-35.
Shenep JL, Hughes WT, Roberson PK, et al. Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 1988;319:1053-8.
EORTC International Antimicrobial Therapy Cooperative Group, National Cancer Institute of Canada Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 1991;163:951-8.
Ramphal R, Bolger M, Obion DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: A randomized prospective study. Antimicrob Agents Chemother 1992;36:1062-7.
Pico JL, Marie JP, Chiche D, et al. Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. Eur J Med 1993;2:275-80.
Hughes WT, Armstrong D, Bodey GP, et al. From the Infectious Diseases Society of America: Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 1990;161:381-96.
De Pauw BE, Deresinski SC, Feld R, Lane-Aliman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: A multicenter randomized trial. Ann Intern Med 1994;120:834-44.
Wade JJ. Enterococcus faecium in hospitals. Eur J Clin Microbiol Infect Dis 1997;16:113-9.
Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.
Suppola JP, Volin L, Valtonen VV, Vaara M. Overgrowth of Enterococcus faecium in the feces of patients with hematologic malignancies. Clin Infect Dis 1996;23:694-7.
Henning KJ, Delencastre H, Eagan J, et al. Vancomycinresistant Enterococcus faecium on a pediatric oncology ward: Duration of stool shedding and incidence of clinical infection. Pediatr Infect Dis J 1996;15:845-7.
Philpott NJ, Brownlee R, Morrison D, et al. Vancomycinresistant enterococci (VRE) on a leukemia/BMT unit [abstract no. 0335]. Bone Marrow Transplant 1997;19(suppl 1):S84.
Recommendations for preventing the spread of vancomycin resistance Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1994;44:1-13.